Welcome to our dedicated page for Haemonetics Corporation news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Corporation stock.
Haemonetics Corporation (NYSE: HAE) is a global leader in blood management solutions, dedicated to improving patient care and reducing healthcare costs. The company offers a comprehensive portfolio of integrated devices, information management systems, and consulting services that address every facet of blood and plasma management. Haemonetics operates through three key segments: Plasma, Blood Center, and Hospital.
In the Plasma segment, Haemonetics focuses on providing innovative technologies for plasma collection and processing. The company's products help ensure a steady supply of high-quality plasma for the production of biopharmaceuticals and other therapeutic applications.
Within the Blood Center segment, Haemonetics offers advanced solutions for blood component collection and processing, aiding in the optimization of blood supply chains. Despite facing high competition in this segment, the company continues to innovate and enhance its product offerings.
The Hospital segment is a significant growth area for Haemonetics, providing essential tools for surgical suites and transfusion services. The company's technologies help prevent unnecessary blood transfusions and ensure the right blood product is used at the right time, improving patient outcomes.
Recently, Haemonetics has achieved several milestones, including the acquisition of Attune Medical, the manufacturer of the FDA-cleared ensoETM® esophageal cooling device. This acquisition strengthens Haemonetics' presence in the electrophysiology market and complements its vascular closure offerings.
Haemonetics also received 510(k) clearance from the U.S. FDA for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge, expanding its capabilities to serve fully heparinized patients in critical surgical procedures.
The company's financial performance remains robust, with a strong focus on revenue growth and strategic investments. Haemonetics continues to explore new markets and develop cutting-edge technologies to stay at the forefront of the healthcare industry.
To stay updated with the latest developments and financial results, Haemonetics regularly hosts investor calls and webcasts, providing transparency and insights into its ongoing projects and future plans.
Haemonetics (NYSE: HAE) has launched a market release of its new VASCADE MVP XL, a mid-bore venous closure device. This device is an extension of the VASCADE portfolio, featuring a collapsible disc and a resorbable collagen patch for rapid hemostasis. The VASCADE MVP XL system utilizes 58% more collagen and is designed for larger procedural sheaths up to 15F in outer diameter. It targets procedures like cryoablation and left atrial appendage closure for atrial fibrillation patients. The device has received pre-market approval from the FDA and the first procedure has been successfully performed by Dr. Tom McElderry at the University of Alabama at Birmingham. Haemonetics aims to capture a share of the $2.7 billion vascular closure market and plans a full market release later this year.
Haemonetics has announced the pricing of an upsized private placement of $600 million in 2.50% Convertible Senior Notes due 2029. The offering size increased from the previously announced $525 million. The notes are senior, unsecured obligations maturing on June 1, 2029, with a conversion price of $117.12 per share, a 30% premium over the last reported sale price. The net proceeds, estimated at $584.8 million, will be used to pay for capped call transactions, repurchase $200 million of 2026 notes, repay a $230 million revolving credit facility, and for other general purposes. Haemonetics has also granted an option to the initial purchasers to buy an additional $100 million in notes. The offering is expected to close on May 28, 2024.
On May 21, 2024, Haemonetics announced its plan to offer $525 million in Convertible Senior Notes due 2029 in a private offering to qualified institutional buyers.
An additional $75 million in notes may be offered if initial purchasers exercise their option. The notes will be senior, unsecured, and accrue interest semi-annually, to be settled in cash or common stock upon conversion.
Proceeds will fund capped call transactions to offset dilution and support general corporate purposes, potentially influencing the market price of Haemonetics' stock.
Haemonetics (NYSE: HAE) released its financial results for the fourth quarter and fiscal year 2024, accessible on its Investor Relations website. The company will host a conference call and webcast to discuss the results. Links to the earnings release and analytical tables are available on the website.
FAQ
What is the current stock price of Haemonetics Corporation (HAE)?
What is the market cap of Haemonetics Corporation (HAE)?
What does Haemonetics Corporation specialize in?
What are the main segments of Haemonetics' business?
What recent acquisitions has Haemonetics made?
What is the TEG® 6s hemostasis analyzer system?
How does Haemonetics support its plasma segment?
What are the financial highlights of Haemonetics?
How does Haemonetics improve patient care?
What was the significance of the FDA clearance for Haemonetics?
What is Haemonetics' approach to innovation?
How can investors stay updated on Haemonetics' performance?
